Structure Therapeutics Inc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
15analysts covering
FY Revenue (est.)
$38.5Mnext fiscal year
FY EPS (est.)
-$1.62next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Body Composition and Type 2 Diabetes/Obesity Supplementary Study Data Readouts | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Aleniglipron (GSBR-1290) Phase 2 ACCESS II Placebo-Adjusted Mean Weight Loss at 44 Weeks (180 mg dose) Annually16.3Target: Comparable to injectable GLP-1 receptor agonists
Aleniglipron (GSBR-1290) Phase 2 ACCESS II Placebo-Adjusted Mean Weight Loss at 44 Weeks (240 mg dose) Annually16.0Target: Comparable to injectable GLP-1 receptor agonists
Total Cash, Cash Equivalents, and Short-Term Investments Quarterly1.5BTarget: Sufficient to fund operations and key clinical milestones through the end of 2028
Watch Items
- Initiation of Phase 3 Registrable Program for Aleniglipron in Chronic Weight ManagementTrigger: Q3 2026Action: Monitor patient enrollment, titration safety profiles starting at 2.5 mg, and clinical site activation.
- Phase 1 Clinical Data Readout for Oral Amylin Receptor Agonist ACCG-2671Trigger: Q3 2026Action: Evaluate safety, tolerability, and pharmacokinetic profiles to support progression to Phase 2a.
- Phase 1 Clinical Trial Initiation of Second Oral Amylin Candidate ACCG-3535Trigger: Q4 2026Action: Verify IND clearance and first-patient-dosed milestones.
Research as of 19 Jun 2026